维生素C稳定CD8+ iTreg并增强其控制小鼠GVHD与白血病复发的作用
该研究在小鼠模型中探讨维生素C(Vit C)处理对CD8+诱导性调节性T细胞(iTreg)稳定性的影响。结果显示,Vit C可提高CD8+ iTreg中Foxp3表达的稳定性,增强其减轻急性和慢性GVHD的能力,同时保留控制肿瘤复发的作用。
要点
- Vit C提高CD8+ iTreg中Foxp3表达的稳定性
- Vit C处理的CD8+ iTreg可减轻急性和慢性GVHD
- 与CD4+ iTreg不同,Vit C处理的CD8+ iTreg保留控制肿瘤复发的能力
核心结论
- Vit C处理可稳定CD8+ iTreg并增强其控制GVHD的疗效,同时保留移植物抗白血病效应,为临床稳定CD8+ iTreg提供了依据。
研究设计与样本
- 研究在CD8+ iTreg培养中加入Vit C,并在小鼠模型中评估其对急性和慢性GVHD及肿瘤复发的作用,同时进行机制研究。
主要发现
- 加入Vit C显著提高CD8+ iTreg中Foxp3表达的稳定性。
- Vit C处理的CD8+ iTreg在减轻急性GVHD和慢性GVHD方面表现出高效性。
- 机制上,Vit C增加保守非编码序列2区域的DNA去甲基化,维持较高的Foxp3表达水平。
- 在急性GVHD中,Vit C处理的CD8+ iTreg抑制致病性T细胞扩增与分化;在慢性GVHD中减少胸腺损伤和B细胞活化。
- 与CD4+ iTreg不同,Vit C处理的CD8+ iTreg保留控制肿瘤复发的能力。
临床怎么用
- 提示临床可考虑用Vit C稳定CD8+ iTreg,以在allo-HCT后控制GVHD并保留GVL效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adoptive transfer of induced regulatory T cells (iTregs) can ameliorate graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (allo-HCT). CD4+ iTregs can effectively prevent GVHD but impair the graft-versus-leukemia (GVL) effect, whereas CD8+ iTregs preserve the GVL effect but have limited efficacy in GVHD control because of their instability under inflammatory conditions. Thus, we aimed to stabilize CD8+ iTregs via treatment with vitamin C (Vit C) to improve their efficacy in controlling GVHD. We found that addition of Vit C significantly improved the stability of forkhead box P3 (Foxp3) expression in CD8+ iTregs. Moreover, Vit C-treated CD8+ iTregs exhibited high efficacy in attenuating acute and chronic GVHD. The mechanistic study revealed that addition of Vit C to CD8+ iTreg culture markedly increased DNA demethylation in the conserved noncoding sequence 2 region and, hence, maintained higher Foxp3 expression levels compared with untreated controls. In acute GVHD, Vit C-treated CD8+ iTregs were able to inhibit pathogenic T-cell expansion and differentiation while reducing thymus damage and B-cell activation in cGVHD. Importantly, in contrast to CD4+ iTregs, Vit C-treated CD8+ iTregs retained the ability to control tumor relapse. These results provide a strong rationale to use Vit C in the clinic to stabilize CD8+ iTregs for the control of GVHD and preservation of GVL after allo-HCT.
引用
- Iamsawat S, Tian L, Daenthanasanmak A, et al. Vitamin C stabilizes CD8+ iTregs and enhances their therapeutic potential in controlling murine GVHD and leukemia relapse. Blood Adv. 2019. PMID: 31856270. doi:10.1182/bloodadvances.2019000531
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。